Phase 3 Breast Cancer Trial, Recruiting NCT07349069 Sponsor: Shandong Suncadia Medicine Co., Ltd. Condition: Breast Cancer
Back to Breast Cancer

Phase 3 Breast Cancer Trial, Recruiting

NCT07349069
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 to 75 years. Women who have not yet reached menopause must also be eligible for a specific hormone-suppressing treatment (called LHRH agonist therapy) to be used during the study period.
  • People with invasive breast cancer confirmed by laboratory testing of tissue after surgery, who have already completed at least 2 years but no more than 5 years of hormone-blocking treatment following surgery.
  • People with no signs that the cancer has come back or spread after surgery.
  • People with a general health score of 0 or 1 on a standard medical scale, meaning fully active or able to carry out light activity (confirm with trial site).
  • People with adequately functioning organs and bone marrow, based on blood tests.
  • Women who could become pregnant must have a negative blood pregnancy test within 7 days before joining the trial, and must be willing to use non-hormonal contraception from the time of signing consent until 7 months after the last dose of the study treatment.
  • People whose side effects from any previous cancer treatment have largely resolved to mild or no symptoms.
  • People who have given written consent and are willing and able to attend scheduled visits and follow all study procedures.

Who may not be able to join:

  • People with stage IV (advanced or metastatic) breast cancer that has spread to other parts of the body.
  • People who have had, or been treated for, any other cancer (besides breast cancer) within the past 5 years.
  • People with a history of serious lung disease, such as a condition involving scarring or inflammation of the lungs.
  • People who are currently using, or may need to use, any other cancer treatment not included in the study plan.
  • People who have had a major surgical procedure within the 4 weeks before joining the trial.
  • People with HIV, AIDS, active hepatitis B, active hepatitis C, or a combination of hepatitis B and C infection.
  • People with poor heart function (confirm with trial site for specific criteria).
  • People who have had a serious infection within the 4 weeks before joining the trial.
  • People with a history of drug allergies.
  • People who have had an organ transplant.
  • People with a history of substance abuse.
  • Women who gave birth within the past year or who are currently breastfeeding.
  • People whom the trial doctor considers unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
4 March 2026
Est. completion
1 December 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The time from the date of randomization to the first occurrence of any of the following events: ipsilateral local or contralateral invasive recurrence, distant recurrence, or death from any cause.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov